Allergen immunotherapy for insect venom allergy

Autor: Franziska Ruëff, Radosław Gawlik, Moises A. Calderon, Darío Antolín-Amérigo, Ewa Cichocka-Jarosz, Ervin Ç. Mingomataj, Markus Ollert, Danijela Bokanovic, Eva-Maria Varga, Joanna Lange, Hadar Zaman, Aziz Sheikh, M. B. Bilò, T. Jakob, V. Pravettoni, Miqdad Asaria, Graham Roberts, Oliver Pfaar, H. N. G. Oude Elberink, Constantinos Pitsios, G. Netuveli, Mitja Košnik, S. Dhami, Antonella Muraro, Holger Mosbech, Cezmi A. Akdis, Betül Ayşe Sin, Dimitris I. Mitsias, Gunter J. Sturm
Přispěvatelé: University of Zurich, Dhami, S
Jazyk: angličtina
Rok vydání: 2017
Předmět:
0301 basic medicine
STINGS
PROTOCOL
Allergy
Cost-Benefit Analysis
CHILDREN
law.invention
DOUBLE-BLIND
0302 clinical medicine
Randomized controlled trial
law
Risk Factors
10183 Swiss Institute of Allergy and Asthma Research
Immunology and Allergy
HYMENOPTERA VENOM
systemic sting reaction
Arthropod Venoms
HYPERSENSITIVITY
ANAPHYLAXIS
Absolute risk reduction
Disease Management
LARGE LOCAL REACTIONS
Treatment Outcome
SUBLINGUAL IMMUNOTHERAPY
Meta-analysis
2723 Immunology and Allergy
Anaphylaxis
Allergen immunotherapy
medicine.medical_specialty
Immunology
610 Medicine & health
CONTROLLED-TRIAL
03 medical and health sciences
hymenoptera venom allergy
medicine
Animals
Humans
Intensive care medicine
Adverse effect
2403 Immunology
business.industry
Insect Bites and Stings
Allergens
medicine.disease
Sting
030104 developmental biology
030228 respiratory system
Desensitization
Immunologic

insect venom allergy
business
Zdroj: Dhami, S, Zaman, H, Varga, E-M, Sturm, G J, Muraro, A, Akdis, C A, Antolin-Amerigo, D, Bilò, M B, Bokanovic, D, Calderón, M A, Cichocka-Jarosz, E, Oude Elberink, J NG, Gawlik, R, Jakob, T, Kosnik, M, Lange, J, Mingomataj, E, Mitsias, D I, Mosbech, H, Ollert, M, Pfaar, O, Pitsios, C, Pravettoni, V, Roberts, G, Ruëff, F, Ayse Sin, B, Netuveli, G & Sheikh, A 2016, ' Allergen immunotherapy for insect venom allergy: a systematic review and meta-analysis ', Allergy . https://doi.org/10.1111/all.13077
ISSN: 0105-4538
1398-9995
Popis: Background: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing the EAACI Guidelines on Allergen Immunotherapy (AIT) for the management of insect venom allergy. To inform this process, we sought to assess the effectiveness, cost-effectiveness and safety of AIT in the management of insect venom allergy.Methods: We undertook a systematic review, which involved searching 15 international biomedical databases for published and unpublished evidence. Studies were independently screened and critically appraised using established instruments. Data were descriptively summarized and, where possible meta-analysed.Results: Our searches identified a total of 16,917 potentially eligible studies of which 17 satisfied our inclusion criteria. The available evidence was limited both in volume and quality, but suggested that venom immunotherapy (VIT) could substantially reduce the risk of subsequent severe systemic sting reactions (OR=0.08, 95% CI 0.03 to 0.26); meta-analysis showed that it also improved disease specific quality of life (risk difference=1.41, 95% CI 1.04 to 1.79). Adverse effects were experienced in both the build-up and maintenance phases, but most were mild with no fatalities being reported. The very limited evidence found on modeling cost-effectiveness suggested that VIT was likely to be cost-effective in those at high risk of repeated systemic sting reactions and/or impaired quality of life.Conclusions: The limited available evidence suggested that VIT is effective in reducing severe subsequent systemic sting reactions and in improving disease specific quality of life. VIT proved to be safe and no fatalities were recorded in the studies included in this review. The cost-effectiveness of VIT needs to be established.
Databáze: OpenAIRE